

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number  
**WO 2005/044187 A3**

(51) International Patent Classification<sup>7</sup>: A61K 9/14,  
AOIN 25/02, 25/00

(21) International Application Number:  
PCT/US2004/035129

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/515,077 28 October 2003 (28.10.2003) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB 6 ONN (GB).

(71) Applicant (for MG only): **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAWSON, Michelle, L.** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 ODP (GB). **ROCHE, Trevor, C.** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 ODP (GB). **WHITAKER, Mark** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 ODP (GB). **CHIDAVANZI, Owen, Chisora** [ZW/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP (GB).

(74) Agents: **LEVY, David, J.** et al; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
23 March 2006


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE AND METHODS OF ADMINISTERING THE SAME

Salmeterol



Fluticasone propionate



Legend (%/type Anhydrous Lactose)

- |                    |                    |                          |                   |
|--------------------|--------------------|--------------------------|-------------------|
| —○— 1% Commercial  | —○— 1% Stable      | ...-△-... 1% Hygroscopic | — Monohydratβ     |
| —△— 10% Commercial | —△— 10% Stable     | ---△--- 10% Hygroscopic  | —×— Monohydrate 2 |
| —×— 80% Commercial | - -×- - 60% Stable |                          |                   |

(57) Abstract: Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and lactose anhydrate.

WO 2005/044187 A3